Incyte Corporation - Asset Resilience Ratio
Incyte Corporation (INCY) has an Asset Resilience Ratio of 7.03% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Incyte Corporation short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (1999–2025)
This chart shows how Incyte Corporation's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see INCY asset base.
Liquid Assets Composition Over Time
This chart breaks down Incyte Corporation's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore how much of Incyte Corporation's assets are long-term investments to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $553.37 Million | 7.03% |
| Total Liquid Assets | $553.37 Million | 7.03% |
Asset Resilience Insights
- Limited Liquidity: Incyte Corporation maintains only 7.03% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Incyte Corporation Industry Peers by Asset Resilience Ratio
Compare Incyte Corporation's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
CSL Ltd
AU:CSL |
Biotechnology | 0.41% |
|
Vaxcyte Inc
NASDAQ:PCVX |
Biotechnology | 41.54% |
|
Bachem Holding AG
SW:BANB |
Biotechnology | 0.00% |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX |
Biotechnology | 38.51% |
|
Chongqing Zhifei Bio Products
SHE:300122 |
Biotechnology | -0.08% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 3.29% |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076 |
Biotechnology | 2.30% |
|
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229 |
Biotechnology | 0.12% |
Annual Asset Resilience Ratio for Incyte Corporation (1999–2025)
The table below shows the annual Asset Resilience Ratio data for Incyte Corporation.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 6.94% | $482.79 Million | $6.96 Billion | -1.70pp |
| 2024-12-31 | 8.64% | $470.26 Million | $5.44 Billion | +2.11pp |
| 2023-12-31 | 6.53% | $442.67 Million | $6.78 Billion | +1.60pp |
| 2022-12-31 | 4.92% | $287.54 Million | $5.84 Billion | -0.97pp |
| 2021-12-31 | 5.89% | $290.75 Million | $4.93 Billion | -2.20pp |
| 2020-12-31 | 8.10% | $288.37 Million | $3.56 Billion | -0.21pp |
| 2019-12-31 | 8.31% | $284.87 Million | $3.43 Billion | -2.06pp |
| 2018-12-31 | 10.37% | $274.34 Million | $2.65 Billion | -1.36pp |
| 2017-12-31 | 11.73% | $270.14 Million | $2.30 Billion | +2.20pp |
| 2016-12-31 | 9.53% | $156.20 Million | $1.64 Billion | -8.96pp |
| 2015-12-31 | 18.50% | $186.34 Million | $1.01 Billion | +0.67pp |
| 2014-12-31 | 17.83% | $147.97 Million | $830.07 Million | +11.86pp |
| 2013-12-31 | 5.97% | $37.58 Million | $629.57 Million | +4.65pp |
| 2012-12-31 | 1.32% | $4.36 Million | $330.42 Million | -0.03pp |
| 2011-12-31 | 1.35% | $4.43 Million | $328.96 Million | +0.07pp |
| 2010-12-31 | 1.28% | $6.26 Million | $489.58 Million | -1.61pp |
| 2009-12-31 | 2.89% | $20.59 Million | $712.39 Million | -5.40pp |
| 2008-12-31 | 8.29% | $19.26 Million | $232.39 Million | -45.24pp |
| 2007-12-31 | 53.53% | $147.58 Million | $275.69 Million | -31.23pp |
| 2006-12-31 | 84.76% | $299.71 Million | $353.60 Million | -4.38pp |
| 2005-12-31 | 89.14% | $333.48 Million | $374.11 Million | +23.83pp |
| 2004-12-31 | 65.31% | $337.58 Million | $516.92 Million | -4.28pp |
| 2003-12-31 | 69.59% | $264.11 Million | $379.55 Million | -3.96pp |
| 2002-12-31 | 73.55% | $406.09 Million | $552.14 Million | +7.71pp |
| 2001-12-31 | 65.84% | $464.54 Million | $705.56 Million | +12.61pp |
| 2000-12-31 | 53.23% | $472.02 Million | $886.82 Million | +37.59pp |
| 1999-12-31 | 15.64% | $34.70 Million | $221.90 Million | -- |
About Incyte Corporation
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chr… Read more